Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
113 hedge funds and large institutions have $227M invested in Cymabay Therapeutics in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 26 increasing their positions, 41 reducing their positions, and 29 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
10% less capital invested
Capital invested by funds: $251M → $227M (-$24.6M)
13% less funds holding
Funds holding: 130 → 113 (-17)
37% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 41
39% less call options, than puts
Call options by funds: $2.1M | Put options by funds: $3.45M
59% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
+$2.42M |
| 2 |
KPWS
Kestra Private Wealth Services
Austin,
Texas
|
+$2.22M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$2.05M |
| 4 |
Morgan Stanley
New York
|
+$1.73M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$765K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$5.45M |
| 2 |
Two Sigma Investments
New York
|
-$3.35M |
| 3 |
BlackRock
New York
|
-$2.34M |
| 4 |
Two Sigma Advisers
New York
|
-$2.08M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.63M |
CBAY Hedge Fund Activity: Q2 2021 in Review
113 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q2 2021, worth a combined $227M — down 9.8% from $251M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of CBAY and 12 opened new positions — a net loss of 17 holders — while 41 trimmed existing stakes and 26 added.
The largest buyer was Commodore Capital, adding an estimated $2.42M. The largest seller was Citadel Advisors, cutting an estimated $5.45M.
- 113 institutional investors held Cymabay Therapeutics (CBAY) as of Q2 2021, down from 130 in Q1 2021.
- Funds reported $227M of Cymabay Therapeutics stock for Q2 2021, down 9.8% quarter-over-quarter.
- 12 funds opened new Cymabay Therapeutics positions in Q2 2021 and 29 closed out, a net change of -17 holders.
- The largest Cymabay Therapeutics buyer in Q2 2021 was Commodore Capital, an estimated $2.42M added.
- The largest Cymabay Therapeutics seller in Q2 2021 was Citadel Advisors, an estimated $5.45M sold.
Based on aggregated 13F filings for Q2 2021.